We are a small german medical device manufacturer. Should we do business with russian companies?

GPT-5.4

Vote: No

No. For a German medical device manufacturer, doing business with Russian companies creates major legal, sanctions, export-control, payment, logistics, and reputational risks. Even if some medical products may be exempt, the compliance burden is high and mistakes can be severe. There is also significant counterparty risk: banking channels, insurance, servicing, spare parts, warranties, and collections can all be disrupted suddenly by new restrictions or operational barriers. As a small company, you likely have limited capacity to manage continuous sanctions screening, end-use checks, distributor oversight, and documentation. That makes the risk-adjusted business case unattractive. If there is a humanitarian or clearly lawful medical need, treat it only as a narrow exception after specialized EU/German sanctions counsel and export-control review. As a general business policy, the prudent answer is no.

Grok 4.1 Fast

Vote: No

As a small German medical device manufacturer, doing business with Russian companies poses severe legal risks due to EU sanctions imposed since Russia's 2022 invasion of Ukraine. Germany, as an EU member, enforces strict export controls; medical devices could fall under dual-use regulations or restricted categories, risking massive fines, criminal penalties, or business shutdowns for non-compliance. Financially, payments are unreliable—many Russian banks are SWIFT-excluded, and currency controls complicate transactions, increasing default risks for a small firm without resources to absorb losses. Reputational damage would be catastrophic: German customers, partners, and regulators view Russia ties negatively amid the war, potentially leading to lost contracts and market exclusion. Operational challenges include supply chain disruptions, logistics bans, and ethical backlash from employees/stakeholders. Safer markets exist in the EU/globally without these hazards—prioritize compliance and stability over high-risk Russian opportunities.

Sonar Pro

Vote: No

A small German medical device manufacturer should not pursue new business with Russian companies due to substantial legal and reputational risks. Legal Compliance: Germany and the EU maintain comprehensive sanctions against Russia, including sectoral restrictions on exports of certain goods and technologies[2]. German companies face severe penalties—including fines and imprisonment under German law—for sanctions violations[2]. The regulatory landscape remains actively enforced, with the EU Council extending financial sanctions until September 2026[6], and Germany's Chancellor explicitly opposing any easing of sanctions as recently as March 2026[7]. Industry-Specific Concerns: Medical devices may fall under dual-use or restricted categories, particularly if they contain semiconductors or advanced components[2]. German companies have faced allegations of products reaching Russia through sanctions circumvention schemes, damaging brand reputation[4]. Operational Risk: For new business relationships, legal guidance explicitly recommends against accepting new orders or concluding new contracts without comprehensive sanctions screening[2]. For a small manufacturer with limited compliance resources, this creates significant operational burden. Market Access: Pursuing Russian business could jeopardize relationships with EU and Western customers, government contracts, and supply chain partnerships that depend on sanctions compliance[2]. Existing contracts might present different considerations, but new business relationships carry unjustifiable risk relative to potential reward.

Claude Opus 4.6

Vote: No

As a small German medical device manufacturer, doing business with Russian companies carries enormous risks that far outweigh potential benefits. **EU Sanctions Compliance:** Since Russia's invasion of Ukraine in 2022, the EU has enacted comprehensive sanctions packages that severely restrict trade with Russia. While some medical devices may fall under humanitarian exceptions, navigating these carve-outs is extraordinarily complex. A small company likely lacks the legal resources to ensure full compliance, and violations carry severe penalties including heavy fines and criminal prosecution under German law. **Reputational Risk:** Doing business with Russian entities carries significant reputational damage in the current geopolitical climate. German customers, partners, and investors may distance themselves from a company perceived as supporting the Russian economy during an active conflict. For a small manufacturer, losing even a few key relationships could be existential. **Payment and Logistics Challenges:** SWIFT restrictions on major Russian banks, export controls, and disrupted logistics corridors make transactions practically very difficult. Currency volatility with the ruble adds financial risk. Insurance and shipping to Russia have become prohibitively expensive or simply unavailable. **Dual-Use Concerns:** Many medical devices contain components or technologies that could fall under dual-use export control regulations (e.g., advanced electronics, sensors, software). German authorities (BAFA) scrutinize exports to Russia intensely, and even seemingly innocent devices could be flagged. **Disproportionate Risk for a Small Company:** A large multinational might absorb the legal costs and compliance overhead of navigating Russian trade. A small manufacturer cannot. One compliance misstep could result in penalties that threaten the company's survival. The prudent course is to avoid Russian business and focus on markets where trade is straightforward and risk-free.

Gemini 3.1 Pro

Vote: No

As a small German medical device manufacturer, engaging in business with Russian companies currently presents disproportionate legal, financial, and reputational risks. While medical devices are often exempt from EU sanctions for humanitarian reasons, the surrounding operational environment is heavily restricted and fraught with complexity. First, the compliance burden is enormous. You must navigate ever-changing export controls, ensure end-users are not sanctioned entities (such as military affiliates), and handle complex customs procedures. A small company typically lacks the dedicated legal and compliance teams required to manage these strict EU regulations safely. Second, financial transactions are highly restricted. With major Russian banks banned from SWIFT, securing payment is incredibly difficult, delayed, or subject to asset freezing. You risk delivering goods without ever receiving compensation, threatening your cash flow. Finally, there is substantial reputational risk. Doing business in Russia right now can severely damage your brand image and relationships with key European and North American partners, investors, and customers. The potential revenue gain is not worth jeopardizing your core markets and overall business stability.

Kimi K2.5

Vote: No

The legal and compliance risks are prohibitive. EU sanctions packages restrict dual-use technologies and many medical device components, creating liability exposure even for humanitarian exemptions. German regulatory authorities actively scrutinize Russian transactions, and accidental violations carry severe penalties. Reputational damage poses an existential threat to a small manufacturer. German healthcare providers and distributors increasingly refuse to partner with companies linked to Russia, potentially cutting you off from your core EU market to chase uncertain Russian revenue. Operational realities make profitable trade nearly impossible. Russian banks are largely cut off from SWIFT, forcing risky payment workarounds. Logistics are disrupted, insurance costs have skyrocketed, and ruble convertibility is unreliable—creating cash flow nightmares for a small firm with limited working capital. The opportunity cost is too high. Resources diverted to navigating sanctions compliance and payment complexities would yield better returns in stable EU markets or Asia-Pacific regions without sanctions baggage.

Final Summary

The AI Roundtable reached a rare and immediate consensus, with all six models warning that the potential revenue from Russia is a 'poisoned chalice' for a small firm. GPT-5.4 and Gemini 3.1 Pro argued that the lack of massive compliance departments makes a legal slip-up almost inevitable, while Sonar Pro and Claude Opus 4.6 emphasized that the reputational stain could lead to an existential exclusion from the manufacturer's core European markets.

All 6 models agreed on "No" after discussion

Strongest Arguments

• No: A small manufacturer lacks the specialized legal infrastructure to safely navigate the thin line between humanitarian exemptions and criminal sanctions violations, making any Russian transaction a potential company-ending event.